Results 191 to 200 of about 25,067 (205)

Olaparib-Resistant BRCA2MUT Ovarian Cancer Cells with Restored BRCA2 Abrogate Olaparib-Induced DNA Damage and G2/M Arrest Controlled by the ATR/CHK1 Pathway for Survival

Cells, 2023
Łukasz Biegała, Arkadiusz Gajek, Agnieszka Marczak   +2 more
exaly  

OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

Annals of Oncology, 2019
Mark E Robson, N Tung, Pierfranco Conte   +2 more
exaly  

A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187

Investigational New Drugs, 2016
Eric X Chen, Lillian L Siu, Lesley Seymour   +2 more
exaly  

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety

Annals of Oncology, 2016
U A Matulonis, S M Domchek, R Shapira-Frommer   +2 more
exaly  

Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors

Annals of Oncology, 2014
Judith Balmaña, S J Isakoff, E Winer
exaly  

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Lancet, The, 2010
James Carmichael, Michael Friedlander, Katherine M Bell-Mcguinn   +2 more
exaly  

A real or apparent decrease in glomerular filtration rate in patients using olaparib?

European Journal of Clinical Pharmacology, 2020
Maaike A C Bruin, Sabine C Linn, B Van Triest   +2 more
exaly  

Olaparib

Reactions Weekly, 2016
openaire   +1 more source

Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer

Annals of Oncology, 2015
J Bendell, Eileen M O'Reilly, M R Middleton   +2 more
exaly  

In vitro assessment of the roles of drug transporters in the disposition and drug–drug interaction potential of olaparib

Xenobiotica, 2017
Helen Swaisland
exaly